- Home
- ABUS vs NBBK Comparison
ABUS vs NBBK Comparison
Compare ABUS & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- NBBK
- Stock Information
- Founded
- ABUS 2005
- NBBK 1892
- Country
- ABUS United States
- NBBK United States
- Employees
- ABUS N/A
- NBBK N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- NBBK
- Sector
- ABUS Health Care
- NBBK
- Exchange
- ABUS Nasdaq
- NBBK Nasdaq
- Market Cap
- ABUS 711.2M
- NBBK 679.8M
- IPO Year
- ABUS N/A
- NBBK N/A
- Fundamental
- Price
- ABUS $4.46
- NBBK $18.25
- Analyst Decision
- ABUS Strong Buy
- NBBK Buy
- Analyst Count
- ABUS 2
- NBBK 1
- Target Price
- ABUS $5.00
- NBBK $22.00
- AVG Volume (30 Days)
- ABUS 930.7K
- NBBK 172.4K
- Earning Date
- ABUS 11-10-2025
- NBBK 10-22-2025
- Dividend Yield
- ABUS N/A
- NBBK 1.57%
- EPS Growth
- ABUS N/A
- NBBK 423.26
- EPS
- ABUS N/A
- NBBK 1.55
- Revenue
- ABUS $15,416,000.00
- NBBK $189,481,000.00
- Revenue This Year
- ABUS $138.02
- NBBK N/A
- Revenue Next Year
- ABUS N/A
- NBBK N/A
- P/E Ratio
- ABUS N/A
- NBBK $11.54
- Revenue Growth
- ABUS 53.23
- NBBK 30.69
- 52 Week Low
- ABUS $2.71
- NBBK $15.09
- 52 Week High
- ABUS $5.10
- NBBK $21.05
- Technical
- Relative Strength Index (RSI)
- ABUS 54.42
- NBBK 55.39
- Support Level
- ABUS $4.26
- NBBK $17.81
- Resistance Level
- ABUS $4.61
- NBBK $18.92
- Average True Range (ATR)
- ABUS 0.20
- NBBK 0.51
- MACD
- ABUS -0.01
- NBBK 0.11
- Stochastic Oscillator
- ABUS 65.45
- NBBK 67.87
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.